Amgen Resolves Repatha Access Kerfuffle With Express Scripts
On eve of congressional hearing, the pharmacy benefit manager assures Amgen that Repatha is available to its employees.
You may also be interested in...
Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.
Rebate expectations appear to have got in the way of fast uptake for some of the leading pharmacy benefit managers, according to comments by executives at the Senate Finance Committee hearing April 9.
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.